Group 1 - Nearly 800 foreign institutions have conducted approximately 9,308 research visits to A-share listed companies since 2025, with Point 72 Asset Management leading with 263 visits [1][2] - Major international banks such as Goldman Sachs and Bank of America have also conducted over 100 research visits this year [2][3] - The primary focus of foreign institutions is on the technology and pharmaceutical sectors, indicating strong interest in these areas [3][5] Group 2 - The top three companies receiving the most foreign institution research visits are Huichuan Technology (733 visits), Mindray Medical (404 visits), and Optoelectronics (331 visits) [3][4] - The technology sector, particularly AI, is expected to drive significant growth in corporate profits, with an estimated annual increase of 3% over the next decade due to cost savings and productivity improvements [5] - The pharmaceutical sector in China is gaining international recognition, with local innovative drug companies entering the global first tier in terms of research pipeline quantity [6]

东北证券指出，2026年有望成为中国医疗器械板块的价值重构年。政策压力并非行业的终点：外有投资 回收期缩短、医院现金流改善促进采购决策，叠加医保/DRG政策优化预期；内有倒逼厂商创新+出海双 线并行；有望开启创新技术加速兑现、全球影响力持续提升的新发展阶段。当前，板块基本面已现拐 点，但机构持仓却处于近年历史低位，或可关注预期差下的投资机遇。 12月25日午后，三大指数集体拉升，白酒、医疗器械等多个低位板块走强。医疗器械指数ETF （159898）盘中上涨1.29%，据iFind数据，盘中该ETF申购3600万份。成分股方面，赛诺医疗涨超 14%，麦澜德涨超11%，伟思医疗、硕世生物等涨超7%，迈瑞医疗、联影医疗、奕瑞科技等多个权重股 走强。 消息面上，第六批国家高价值耗材集采启动，引入多重机制防止恶意低价。据智通财经12月23日报道， 新一批国家组织高值医用耗材集采正式启动，将对药物涂层球囊类、泌尿介入类医用耗材进行集采，于 2026年1月13日开标。与前五轮高值医用耗材的集中采购不同，此轮集采有两个新亮点：一是引入了锚 点价格的概念，二是引入了多重复活机制。 此外，据中国证券报，12月25日，国家药监局《 ...

产业链来看，医疗器械是指直接或间接用于人体的仪器、设备、器具、体外诊断试剂及校准物、材料等，其上游涵盖原材料供应、核心零部件制造与研发设 计服务等基础保障，中游是产业链的核心引擎，涵盖产品研发、生产制造、注册认证、流通分销等环节，均具有高壁垒特征。 目前医疗器械指数ETF（159898）跟踪中证全指医疗器械，标的指数细分行业主要分布在医疗设备、医疗耗材、体外诊断等板块，重仓迈瑞、联影、奕瑞科 技等细分龙头，百分之百聚焦A股医疗器械，β质地纯粹，或可更好把握板块整体机遇。 从市值占比上来看，该指数创业板+科创板合计占比超80%，科技成长特性亦较为突出。 | 医疗器械指数ETF159898 2 | | | +1.10% 20日 +0.00% | | --- | --- | --- | --- | | | | | 60日 -7.24% 120日 +5.15% | | 0. 551 +0.008 +1.473% | | | 年初至今+5.76% 250日 +1.47% 52周島高 0 551 52周島任 0 542 | | 委比 +41.06% 94567 | | ੜ੍ਹ ਸਿ | 甲阿 15-0 | | 5 | 0 ...

Core Viewpoint - The strategic partnership between BOE Technology Group and Mindray Medical aims to deepen collaboration in various fields, particularly in medical device supply chains and smart healthcare solutions [1][3]. Group 1: Strategic Collaboration - The partnership will enhance cooperation in core monitoring devices, ultrasound imaging, and in-vitro diagnostics, focusing on display products [1]. - Both companies will leverage their strengths to create comprehensive smart hospital solutions, improving diagnostic capabilities and operational efficiency through digital means [3]. - The collaboration will also push for the launch of a new generation of flat panel detectors equipped with existing X-ray solutions [3]. Group 2: Industry Trends and Company Initiatives - The healthcare sector is becoming a key focus for panel manufacturers due to its high added value and resilience against economic cycles [5]. - BOE has been investing in the healthcare industry since 2015, with a total investment of approximately 17 billion yuan in building hospitals across several cities, totaling around 5,600 planned beds [5]. - The smart healthcare segment under BOE's "1+4+N" ecosystem is projected to generate revenue of 1.839 billion yuan in 2024, reflecting a year-on-year growth of 9.73% [5]. Group 3: Competitor Activities - AUO (友达光电) is also actively expanding in the healthcare sector, covering various medical scenarios through its subsidiaries [6]. - The company has developed an immersive rehabilitation system for elderly care using Micro LED transparent displays and 3D AI imaging technology, achieving a compound annual growth rate of about 20% in recent years [8]. - AUO's healthcare revenue has surpassed 10 billion New Taiwan dollars, indicating strong growth compared to the industry average [8]. Group 4: Market Outlook - The aging population and increasing health demands are expected to create broader development opportunities in the healthcare industry [9]. - Panel companies are positioned to play a significant role in smart healthcare due to their expertise in display technology, sensor technology, and IoT solutions [9].

Core Insights - The report recommends focusing on the CXO sector within the pharmaceutical and biotechnology industry, highlighting its global competitiveness and long-term growth potential [6][4] - The investment strategy maintains an "outperform" rating for the sector, with a specific portfolio of recommended stocks for December 2025 [2][6] Industry Overview - The pharmaceutical manufacturing industry saw a cumulative revenue of 199.55 billion yuan from January to October 2025, reflecting a year-on-year decline of 2.9%, while total profits decreased by 3.5% to 26.98 billion yuan [10][9] - The retail sales of Western and Chinese medicines reached 595.5 billion yuan, with a modest growth of 1.5% year-on-year [10][9] Investment Strategy - The recommended investment portfolio for December 2025 includes notable A-shares such as Mindray Medical (迈瑞医疗), WuXi AppTec (药明康德), and Aier Eye Hospital (爱尔眼科), among others [6][7] - The report emphasizes the importance of monitoring the clinical progress and data readouts of innovative drugs in overseas markets, as these factors can enhance the commercial viability of domestic products [6] Market Performance - The pharmaceutical sector experienced a decline of 3.62% in November 2025, underperforming the CSI 300 index by 1.16% [11] - The medical services sub-sector faced the most significant drop, with a decrease of 7.77%, while the pharmaceutical commercial sector saw a slight increase of 1.27% [17][11] Valuation Insights - The overall valuation of the pharmaceutical sector is relatively high, with a current PE (TTM) of 37.71, placing it at the 79.87 percentile of its historical range over the past five years [19][20] - The premium rates of the pharmaceutical sector compared to the CSI 300 and the entire A-share market remain at historical averages [19][20] Recent Developments - In November 2025, eight innovative drugs or biosimilars were approved for market entry, including products from Pfizer and domestic companies, indicating a robust pipeline for new therapies [25][26] - The report tracks the NDA and IND applications for innovative drugs, highlighting ongoing research and development activities within the industry [27][28]

Investment Rating - The industry rating is "Overweight" and has been maintained from the previous rating [4] Core Insights - The global IVD market is projected to grow from USD 66.7 billion in 2018 to USD 186.1 billion by 2030, with a CAGR of 8.9% [12] - The Chinese IVD market is expected to increase from RMB 71.3 billion in 2018 to RMB 415.2 billion by 2030, with a CAGR of 15.8%, significantly outpacing the global average [13] - The immunodiagnostics market in China is experiencing rapid growth, with a market size increase from RMB 37.3 billion in 2021 to RMB 50.3 billion in 2023, reflecting a CAGR of 16.13% [16] - The POCT market is also expanding quickly, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023, with a CAGR of 19.52% [20] - The molecular diagnostics market, despite a decline from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, still shows potential with a market size exceeding RMB 10 billion when excluding emergency-related factors [25] Summary by Sections IVD Market Outlook - The IVD industry began in the 1950s and has seen significant growth due to advancements in medical technology and increasing health demands [11] - The Chinese IVD market has diversified into various diagnostic technologies, including biochemical, immunological, POCT, molecular, and pathological diagnostics [15] Immunodiagnostics Market - The immunodiagnostics market is the largest segment in China's IVD market, accounting for over 40% in 2023 [15] - The market is expected to face some deceleration due to price reductions from centralized procurement policies [16] Biochemical Diagnostics Market - The biochemical diagnostics market in China grew from RMB 17.1 billion in 2021 to RMB 19 billion in 2023, with a CAGR of 5.41% [19] - Domestic products dominate this market with over 70% market share [19] POCT Market - The POCT market is driven by convenience and increased demand for home testing, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023 [20] Molecular Diagnostics Market - The molecular diagnostics market has faced challenges, declining from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, primarily due to reduced demand post-pandemic [25] Pathogen Microbiology Market - The pathogen microbiology diagnostics market in China is projected to grow from RMB 16.82 billion in 2018 to RMB 90.27 billion by 2030, with a CAGR of 15.0% [30]

Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

Core Viewpoint - The Shenzhen Stock Exchange has initiated the "Quality and Return Dual Improvement" special action to enhance the quality of listed companies and increase investor returns, aiming to solidify the foundation for healthy capital market development [1] Group 1: Special Action Overview - The special action was officially launched in February 2024, with 471 companies disclosing their action plans by November 2025, focusing on enhancing core business awareness, improving innovation capabilities, and increasing investor returns [1][2] - The participating companies include 293 from the Shenzhen Component Index, 88 from the CSI 300 Index, and 82 from the ChiNext Index, collectively representing about 50% of the total market capitalization of the Shenzhen market [2] Group 2: Quality Improvement Paths - Companies are focusing on three main paths: deepening core business, advancing technological innovation, and ensuring regulatory compliance, which helps transform scale advantages into quality advantages [2] - For instance, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is investing heavily in R&D and global expansion to enhance product sophistication and achieve breakthroughs in its digital transformation [2] Group 3: Enhancing Investor Returns - Companies are implementing various practical measures to convert quality improvements into tangible returns for investors, with dividends and share buybacks being key methods for enhancing shareholder returns [4] - Active involvement from controlling shareholders and management is crucial for stabilizing market confidence and increasing shareholder value [5] - Companies are also improving communication channels with investors to build trust and maintain close interaction through diversified and institutionalized mechanisms [5] - In the context of growing emphasis on sustainable development, companies are promoting ESG practices to deepen value creation [5][6]

Core Insights - The "Annual Innovation Award" was awarded to Mindray Medical (300760.SZ) during the "Technology Empowerment · Capital Breakthrough" online sharing session held by Gelonghui on December 22 [1] - The award recognizes companies in the capital market that demonstrate breakthrough and innovative capabilities, emphasizing that innovation is a core competitive advantage for businesses [1] Summary by Categories Award Recognition - Mindray Medical received the "Annual Innovation Award" for its commitment to innovation in technology research and development, products, and business models [1] - The award selection process involved quantitative data analysis and evaluation by an expert review panel [1] Innovation Focus - The "Annual Innovation Award" aims to highlight companies that explore cutting-edge technology and create new development paths, leading the industry forward and promoting social progress [1] - The award criteria considered the breadth and depth of innovation among the nominated companies [1]

Group 1 - The core focus of the event is the announcement of the "Annual Innovation Award" winners, recognizing companies with significant breakthroughs and innovations in the capital market [1] - The awarded companies include Guangfeng Technology, Corning Jereh Pharmaceutical-B, KEEP, Mindray Medical, Ruihe Zhizhi, AAC Technologies, 37 Interactive Entertainment, Tongwei Co., Xinghuan Technology-U, and Ginkgo Bioworks, with no specific ranking [1] - The "Annual Innovation Award" aims to highlight companies that excel in innovation across various dimensions, including technology research and development, products, and business models [1] Group 2 - The "Golden Award" evaluation is designed to create a reference list of the most valuable listed companies and unicorns in the investment community, covering all listed companies on major exchanges [2] - The evaluation includes companies listed on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [2]